title: Three months of octreotide treatment decreases gastric acid secretion and argyrophil cell density in patients with Zollinger-Ellison syndrome and antral G-cell hyperfunction.
abstract: METHODS
  The effects of three months of treatment with octreotide on gastric acid hypersecretion induced by hypergastrinaemia were investigated in patients with Zollinger-Ellison syndrome (n = 5) or antral G-cell hyperfunction (n = 4). Gastric acid secretion, fasting plasma gastrin concentrations and clinical findings were examined, and a morphometrical analysis of oxyntic endocrine cells was performed.
  
  
  RESULTS
  Administration of octreotide 100 mcg b.d. subcutaneously significantly decreased the volume density of argyrophil cells (P < 0.05) as well as basal and pentagastrin-stimulated acid secretion (P < 0.05). Although partial or complete loss of inhibition was found in most patients after 3 months, gastrin levels were decreased during the first 2 months of treatment (P < 0.05). Fundic D-cells were not affected by treatment. Positive correlations were observed between volume density of argyrophil cells and basal acid output (r = 0.65); plasma gastrin and basal acid output (r = 0.74); plasma gastrin concentrations and volume density of argyrophil cells (r = 0.80).
  
  
  CONCLUSIONS
  These results support the important role of the enterochromaffin-like cell in maintaining acid secretion, and indicate a specific role for octreotide in the therapy of gastric acid hypersecretion associated with hypergastrinaemic diseases.
authors.affiliation: Cattedra di Gastroenterologia I, Università di Parma, Italy.
authors.forename: B
authors.initials: B
authors.lastname: Annibale
authors.forename: G
authors.initials: G
authors.lastname: Delle Fave
authors.forename: C
authors.initials: C
authors.lastname: Azzoni
authors.forename: V
authors.initials: V
authors.lastname: Corleto
authors.forename: G
authors.initials: G
authors.lastname: Camboni
authors.forename: G
authors.initials: G
authors.lastname: D'Ambra
authors.forename: F P
authors.initials: FP
authors.lastname: Pilato
authors.forename: C
authors.initials: C
authors.lastname: Bordi
mesh_terms: D000284:Administration, Oral; D000328:Adult; D002452:Cell Count / Q000187:drug effects; D004759:Enterochromaffin Cells / Q000187:drug effects* / Q000473:pathology; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D005755:Gastrins / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D011706:Pyloric Antrum / Q000187:drug effects* / Q000473:pathology; D013004:Somatostatin / Q000378:metabolism; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
chemical_list: D005755:Gastrins; D013004:Somatostatin; D015282:Octreotide